Short Interest Coverage: Akebia Therapeutics Incorporated (NASDAQ:AKBA) Sellers Covered 1.97% of Their Shorts

November 23, 2016 - By Linda Rogers   ·   0 Comments

Short Interest Coverage: Akebia Therapeutics Incorporated (NASDAQ:AKBA) Sellers Covered 1.97% of Their Shorts

The stock of Akebia Therapeutics Incorporated (NASDAQ:AKBA) registered a decrease of 1.97% in short interest. AKBA’s total short interest was 2.18M shares in November as published by FINRA. Its down 1.97% from 2.22 million shares, reported previously. With 90,200 shares average volume, it will take short sellers 24 days to cover their AKBA’s short positions. The short interest to Akebia Therapeutics Incorporated’s float is 14.07%. About 103,013 shares traded hands. Akebia Therapeutics Inc (NASDAQ:AKBA) has declined 6.17% since April 21, 2016 and is downtrending. It has underperformed by 11.49% the S&P500.

Akebia Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $347.60 million. The Firm is focused on the development of therapeutics based on hypoxia inducible factor biology, and the commercialization of these products for patients with serious medical needs. It currently has negative earnings. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

Insitutional Activity: The institutional sentiment decreased to 1.05 in Q2 2016. Its down 0.16, from 1.21 in 2016Q1. The ratio fall, as 13 funds sold all Akebia Therapeutics Inc shares owned while 25 reduced positions. 12 funds bought stakes while 34 increased positions. They now own 19.00 million shares or 7.09% less from 20.45 million shares in 2016Q1.
Northern Tru Corp, a Illinois-based fund reported 371,104 shares. Nantahala Cap Management Ltd Liability last reported 1.36% of its portfolio in the stock. Fifth Third State Bank accumulated 6,600 shares or 0% of the stock. Tower Cap Limited Liability Corporation (Trc) holds 0% of its portfolio in Akebia Therapeutics Inc (NASDAQ:AKBA) for 898 shares. Moreover, Venbio Select Advisor Limited Liability Corporation has 1.03% invested in Akebia Therapeutics Inc (NASDAQ:AKBA) for 621,873 shares. The Texas-based Dimensional Fund Advisors Limited Partnership has invested 0% in Akebia Therapeutics Inc (NASDAQ:AKBA). Blackrock Advisors Ltd Llc accumulated 16,531 shares or 0% of the stock. Tudor Inv Et Al, a Connecticut-based fund reported 18,798 shares. Financial Bank Of Montreal Can accumulated 0% or 223 shares. Visium Asset Management L P last reported 21,526 shares in the company. Wells Fargo Mn reported 83,123 shares or 0% of all its holdings. Envestnet Asset Management last reported 0% of its portfolio in the stock. Tiaa Cref Investment Management Limited Liability Company has 111,642 shares for 0% of their US portfolio. Geode Capital Mgmt Ltd Liability Com last reported 0% of its portfolio in the stock. Blackrock Fund Advsr holds 0% of its portfolio in Akebia Therapeutics Inc (NASDAQ:AKBA) for 1.41M shares.

Insider Transactions: Since July 5, 2016, the stock had 0 insider buys, and 6 selling transactions for $81,138 net activity. Nash Duane also sold $14,819 worth of Akebia Therapeutics Inc (NASDAQ:AKBA) on Wednesday, July 6. 1,401 shares were sold by Dahan Michel, worth $12,546 on Saturday, October 1. Hadas Nicole R. had sold 1,557 shares worth $11,625.

Akebia Therapeutics Inc (NASDAQ:AKBA) Ratings Coverage

Out of 7 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Akebia Therapeutics Inc has been the topic of 12 analyst reports since August 13, 2015 according to StockzIntelligence Inc. H.C. Wainwright maintained it with “Buy” rating and $25.0 target price in Tuesday, December 15 report. The firm earned “Buy” rating on Wednesday, September 9 by Brean Capital. The stock has “Buy” rating given by H.C. Wainwright on Tuesday, March 15. The stock has “Buy” rating given by Brean Capital on Thursday, August 13. The stock has “Buy” rating given by Brean Capital on Thursday, September 29. The firm earned “Buy” rating on Monday, December 7 by H.C. Wainwright. Needham maintained the stock with “Buy” rating in Tuesday, December 15 report. On Tuesday, November 15 the stock rating was initiated by Aegis Capital with “Buy”. JMP Securities maintained the shares of AKBA in a report on Wednesday, March 9 with “Market Outperform” rating. Morgan Stanley initiated Akebia Therapeutics Inc (NASDAQ:AKBA) rating on Thursday, August 13. Morgan Stanley has “Equal Weight” rating and $10 price target.

AKBA Company Profile

Akebia Therapeutics, Inc., incorporated on February 27, 2007, is a biopharmaceutical company. The Firm is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy for the treatment of anemia in CKD subjects not on dialysis and in subjects on dialysis.

More important recent Akebia Therapeutics Inc (NASDAQ:AKBA) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on March 21, 2014, also Fool.com published article titled: “Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today”, Bizjournals.com published: “Cincinnati startup raises $100 million in IPO, stock soars” on March 20, 2014. More interesting news about Akebia Therapeutics Inc (NASDAQ:AKBA) was released by: Finance.Yahoo.com and their article: “Akebia Therapeutics reports 3Q loss” with publication date: November 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>